GNCA News and Press, Genocea Biosciences Inc. From 02/13/20

ATLAS TM identifies Inhibigens tm that can undermine immunotherapy Dosed first patient in Part B of GEN-009 neoantigen vaccine Phase 1/2a trial Progressed GEN-011 neoantigen cell therapy - IND filing expected in Q2 2020 Appointed Dr. Gisela Schwab to Genocea’s Board o...

CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2019 financial results and corporate update conference call and live audio webcast ...

Agilent (NYSE: A ) initiated with Hold rating and $85 (11% upside) price target at Stifel. More news on: Agilent Technologies, Inc., Avantor, Inc., Bio-Techne Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at t...

ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccination Inhibitory T cell responses exacerbate tumor growth CAMBRIDGE, Mass., Nov. 09, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GN...

     Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapy Confirm positive GEN-009 clinical immunogenicity results CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE N...

Genocea Biosciences Inc (GNCA) Q3 2019 Results Earnings Conference Call October 24, 2019 08:30 AM ET Company Participants Dan Ferry - Managing Director, LifeSci Advisors Chip Clark - President and CEO Diantha Duvall - CFO Tom Davis - Chief Medical Officer Jessica Flechtner ...

Cellect Biotechnology (NASDAQ: APOP ) +43%  after reverse split & ADS ratio change. More news on: Cellect Biotechnology Ltd., PDS Biotechnology Corporation, Genocea Biosciences, Inc., Stocks on the move, Read more ...

Genocea Biosciences ( GNCA ) Q3 results : Revenues: $0; R&D Expense: $6.8M (+6.2%); SG&A: $2.7M (-34.1%); Operating loss: ($9.6M) (+8.6%); Net loss: ($7.5M) (+3.8%); loss/share: ($0.28) (+61.1%); Quick Assets: $46.6M (+76.5%). More news on: Genocea Biosciences, Inc., Healthcare st...

Genocea Biosciences (NASDAQ: GNCA ): Q3 GAAP EPS of -$0.28 beats by $0.18 . More news on: Genocea Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...